Bayesian sample size for exploratory clinical trials incorporating historical data

被引:37
|
作者
Whitehead, John [1 ]
Valdes-Marquez, Elsa [2 ]
Johnson, Patrick [3 ]
Graham, Gordon [3 ]
机构
[1] Univ Lancaster, Fylde Coll, Dept Math & Stat, MPS Res Unit, Lancaster LA1 4YE, England
[2] Univ Reading, Sect Quantitat Biol & Appl Stat, Reading, Berks, England
[3] Pfizer Global Res & Dev, Sandwich, Kent, England
关键词
Bayesian methods; clinical trial; phase II trial; proof-of-concept study; sample size; score statistic;
D O I
10.1002/sim.3140
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
This paper presents a simple Bayesian approach to sample size determination in clinical trials. It is required that the trial should be large enough to ensure that the data collected will provide convincing evidence either that an experimental treatment is better than a control or that it fails to improve upon control by some clinically relevant difference. The method resembles standard frequentist formulations of the problem, and indeed in certain circumstances involving 'non-informative' prior information it leads to identical answers. In particular, unlike many Bayesian approaches to sample size determination, use is made of an alternative hypothesis that an experimental treatment is better than a control treatment by some specified magnitude. The approach is introduced in the context of testing whether a single stream of binary observations are consistent with a given success rate p(0). Next the case of comparing two independent streams of normally distributed responses is considered, first under the assumption that their common variance is known and then for unknown variance. Finally, the more general situation in which a large sample is to be collected and analysed according to the asymptotic properties of the score statistic is explored. Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:2307 / 2327
页数:21
相关论文
共 50 条
  • [41] Bayesian sample-size determination methods considering both worthwhileness and unpromisingness for exploratory two-arm randomized clinical trials with binary endpoints
    Kakizume, Tomoyuki
    Zhang, Fanghong
    Kawasaki, Yohei
    Daimon, Takashi
    [J]. PHARMACEUTICAL STATISTICS, 2020, 19 (01) : 71 - 83
  • [42] A Review of Bayesian Perspectives on Sample Size Derivation for Confirmatory Trials
    Kunzmann, Kevin
    Grayling, Michael J.
    Lee, Kim May
    Robertson, David S.
    Rufibach, Kaspar
    Wason, James M. S.
    [J]. AMERICAN STATISTICIAN, 2021, 75 (04): : 424 - 432
  • [43] Sample Size and Data Monitoring for Clinical Trials With Extremely Low Incidence Rates
    Chow, Shein-Chung
    Chiu, Shih-Ting
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2013, 47 (04) : 438 - 446
  • [44] Sample Size and Data Monitoring for Clinical Trials With Extremely Low Incidence Rates
    Shein-Chung Chow
    Shih-Ting Chiu
    [J]. Therapeutic Innovation & Regulatory Science, 2013, 47 : 438 - 446
  • [45] Effects of correlation and missing data on sample size estimation in longitudinal clinical trials
    Zhang, Song
    Ahn, Chul
    [J]. PHARMACEUTICAL STATISTICS, 2010, 9 (01) : 2 - 9
  • [46] Sample size calculations with multiplicity adjustment for longitudinal clinical trials with missing data
    Lu, Kaifeng
    [J]. STATISTICS IN MEDICINE, 2012, 31 (01) : 19 - 28
  • [47] The methods for handling missing data in clinical trials influence sample size requirements
    Auleley, GR
    Giraudeau, B
    Baron, G
    Maillefert, JF
    Dougados, M
    Ravaud, P
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2004, 57 (05) : 447 - 453
  • [48] Some observations on the Makuch/Simon approach to sample size determination in clinical trials with historical controls
    Kepner, J
    Wackerly, D
    [J]. COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION, 2001, 30 (03) : 611 - 621
  • [49] Sample size and clinical trials in pediatric resuscitation
    Edmunds, Katherine
    Zhang, Yin
    Kerrey, Benjamin T.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF EMERGENCY PHYSICIANS OPEN, 2021, 2 (04)
  • [50] On Cost Effectiveness and Sample Size in Clinical Trials
    Augustinus A. M. Hart
    Marcel G. W. Dijkgraaf
    [J]. PharmacoEconomics, 2004, 22 : 685 - 688